SUPRIYA LIFESCIENCE
|
|
BOM : 543434     NSE : SUPRIYA     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : NA |
Dec 05,2024 |
Price(EOD): ₹ 778.05
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 6,263.30 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SUPRIYA LIFESCIENCE | 0.2% | 22.8% | 184.2% |
SUN PHARMACEUTICAL INDUSTRIES | 1.6% | 0.1% | 46.2% |
CIPLA | -2.3% | -5.4% | 24.4% |
DR REDDYS LABORATORIES | 3.2% | -2.2% | 5.8% |
ZYDUS LIFESCIENCES | 1.3% | -2.6% | 51.8% |
DIVIS LABORATORIES | -1.2% | 3.4% | 65% |
MANKIND PHARMA | 2.2% | -4.2% | 35.5% |
TORRENT PHARMACEUTICALS | 1.1% | 5.1% | 55.7% |
LUPIN | 3.7% | -2.9% | 62.1% |
FUNDAMENTAL ANALYSIS OF SUPRIYA LIFESCIENCE
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SUPRIYA LIFESCIENCE
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
39.76
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 157.51 Cr
[Latest Qtr - Sep2024 - Standalone Results ] 7.68
P/B Calculated based on Book Value of Rs 815.37 Cr
[Latest Year - Mar2024 - Standalone Results ] 10.02
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
604% 916% 74% |
SHARE PRICE MOMENTUM OF SUPRIYA LIFESCIENCE
SUPRIYA LIFESCIENCE vs SENSEX
DEBT OF SUPRIYA LIFESCIENCE
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0.02 0.03 0.02 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SUPRIYA LIFESCIENCE
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SUPRIYA LIFESCIENCE
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
3.41% 3.48% 3.83% 3.37% |
18.56% 103.82% 108.42% 93.22% |
QtrlyTrend |
8 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
SUPRIYA LIFESCIENCE related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 4.1% | 1% | 46.7% |
S&P BSE SMALL CAP | 3.5% | 2% | 40.5% |
S&P BSE MIDSMALLCAP | 3.4% | 3% | 40.6% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
You may also like the below Video Courses
FAQ about SUPRIYA LIFESCIENCE
Is SUPRIYA LIFESCIENCE good for long term investment?
As on Dec 05,2024, the Fundamentals of SUPRIYA LIFESCIENCE look Strong and hence it may be good for long term investment! See Financial Performance of SUPRIYA LIFESCIENCE . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SUPRIYA LIFESCIENCE UnderValued or OverValued?
As on Dec 05,2024, SUPRIYA LIFESCIENCE is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SUPRIYA LIFESCIENCE ?
As on Dec 05,2024, the Intrinsic Value of SUPRIYA LIFESCIENCE is Rs. 110.51 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 110.51
Fair Value [Median EV / Sales Model] : Rs. 76.58
Fair Value [Median Price / Sales Model] : Rs. 447.85
Estimated Median Fair Value of SUPRIYA LIFESCIENCE : Rs. 110.51
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.